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Abstract 
Rationale: Phosphodiesterase 2 (PDE2) is a dual substrate esterase, which has the unique 
property to be stimulated by cGMP, but primarily hydrolyses cAMP. Myocardial PDE2 is 
upregulated in human heart failure (HF), but its role in the heart is unknown.  
Objective: To explore the role of PDE2 in cardiac function and heart disease. 
Methods and Results: Pharmacological inhibition of PDE2 (BAY 60-7550, BAY) led to a 
significant positive chronotropic effect on top of maximal β-adrenoceptor (β-AR) activation in 
healthy mice. Under pathological conditions induced by chronic catecholamine infusions, 
BAY reversed both the attenuated β-AR mediated inotropy and chronotropy. Conversely, 
ECG telemetry in heart specific PDE2 transgenic mice (TG) showed a marked reduction in 
resting as well as in maximal heart rate, while cardiac output was completely preserved due 
to greater cardiac contraction. This well tolerated phenotype persisted in elderly TG with no 
indications of cardiac pathology or premature death. Molecular studies on the cardiomyocyte 
level showed lower β-AR stimulation of contractility, Ca2+ transients and L-Type Ca2+ current. 
During arrhythmia provocation induced by catecholamine injections, TG animals were 
resistant to triggered ventricular arrhythmias. Accordingly, Ca2+-spark analysis in isolated TG 
cardiomyocytes revealed remarkably reduced Ca2+-leakage and lower basal phosphorylation 
levels of Ca2+-cycling proteins including ryanodine receptor type 2. Moreover, TG 
demonstrated attenuated ventricular dysfunction and a strong trend toward prolonged 
survival after myocardial infarction. 
Conclusion: Endogenous PDE2 contributes to heart rate regulation. Greater PDE2 
abundance protects against arrhythmias and improves contraction force after severe cardiac 
insult. Activating myocardial PDE2 may thus represent a novel intracellular anti-adrenergic 
therapeutic strategy protecting the heart from arrhythmia and contractile dysfunction. 
 
Key words: phosphodiesterase, -adrenoceptors, heart rate, arrhythmia 
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Nonstandard Abbreviations and Acronyms 
AR  adrenoceptor 
BAY  PDE2-inhibitor BAY 60-7550 
BPs  systolic blood pressure 
BPd  diastolic blood pressure 
bpm  beats per minute 
BW  body weight 
cAMP  cyclic adenosine monophosphate 
cGMP  cyclic guanosine monophosphate 
CO  cardiac output 
CSQ  calsequestrin 
DOBU  dobutamine 
FAS  fractional area shortening 
HF  heart failure 
HR  heart rate 
ICa,L  L-type Ca2+ channel current 
ISO  isoproterenol 
IVA  ivabradine 
LAD  left anterior descending coronary artery 
LTCC  L-type Ca2+ channel 
LVW  left ventricular weight 
METO  metoprolol 
MI  myocardial infarction 
NCX  sodium-calcium exchanger 
NO  nitric oxide 
NP  natriuretic peptide 
PDE  phosphodiesterase 
PLB  phospholamban 
RYR2  ryanodine receptor type 2 
SCaW  spontaneous Ca2+ waves 
SR  sarcoplasmic reticulum 
TG  PDE2-transgenic  
VT  ventricular tachycardia 
WT  wildtype 
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Heart failure (HF) is among the most common causes of morbidity and mortality worldwide. A 
characteristic feature of this pathophysiological condition is a chronic activation of the 
sympathetic nervous system1. Although initially aimed to maintain cardiac output, constant 
stimulation of β-adrenoceptors (β-ARs) results in molecular and structural changes, such as 
hypertrophy, cardiac fibrosis, and electromechanical dysfunction. This process creates a 
setting for lethal cardiac arrhythmias, which may account for approximate 40% of deaths in 
patients with HF2, 3. Moreover, increased resting heart rate and lower heart rate variability are 
significant prognostic risk factors for mortality and cardiovascular outcome4, 5. The 
sympathetically stressed heart responds with desensitization mechanisms which involve the 
reduction of functional β1-AR and the redistribution β2-AR at the plasma membrane6, 7, but 
also a modulation in abundance and/or activity of intracellular key effectors, downstream of 
receptor activation8, 9. Even though β-AR desensitization may further compromise contractile 
performance, it nevertheless appears to be a protective adaptation against catecholamine 
toxicity10. Accordingly, pharmacological blockade of receptor activation by β-blockers to date 
is a central strategy in attenuating HF progression11. In this context, the extent of heart rate 
reduction by β-blockers appears to be of particular importance for the clinical outcome in 
HF12. However, not all patients receive or tolerate the necessary dose to substantially 
improve prognosis13.  
In contrast to β-AR signaling, which is mainly mediated by the second messenger cyclic 
adenosine monophosphate 14, the actions of cyclic guanosine monophosphate (cGMP) 
generated by either natriuretic peptides (NP) or nitric oxide (NO) are considered to be 
beneficial in HF partially because they may oppose cAMP-induced stress remodeling15-18. 
Both cAMP and cGMP are regulated in level and subcellular distribution by cyclic nucleotide 
hydrolyzing phosphodiesterases (PDEs). Their degradation is a highly compartmentalized 
process, allowing the distinction of different extracellular stimuli to maintain the specificity of 
downstream target activation19. Among the PDE families expressed in the heart, PDE2 has 
the unique property to be activated by cGMP via binding of the nucleotide to a regulatory 
GAF-B domain located at its N-terminus20, 21. The conformational change induced by this 
allosteric mechanism increases cAMP hydrolysis 10- to 30-fold thus staging PDE2 in the 
center of a negative cGMP/cAMP crosstalk22. Evidence for such a crosstalk regarding the 
cardiovascular system includes the cGMP-mediated decrease in ventricular and atrial L-type 
Ca2+ channel current (ICa,L) in various species including man23, 24, β3-AR-dependent regulation 
of protein kinase A in cardiomyocytes25, and the ANP-mediated reduction in aldosterone 
production in adrenal glomerulosa cells26. Unlike the described downregulation of cAMP-
degrading PDE3 and some isoforms of PDE427, 28, myocardial PDE2 is upregulated in human 
HF. We showed that the upregulation of ventricular PDE2 is a direct consequence of chronic 
β-AR overstimulation and part of the β-AR desensitization machinery29. However, the 
consequences of higher abundance and activity of PDE2 on cardiac function are largely 
unknown. 
In the present study, we show that in healthy hearts, PDE2 tonically reduces heart rate, but 
controls both β-AR chronotropic and inotropic responsiveness under stressed conditions in 
vivo. Moreover, we generated a cardiac PDE2-transgenic (TG) mouse line to evaluate short 
and long term effects of chronically increased PDE2 activity in the heart. Our study reveals 
that greater PDE2 abundance lowers heart rate without impairment of cardiac contractility in 
vivo and protects against ventricular arrhythmias by preventing Ca2+-leakage from the 
sarcoplasmic reticulum (SR). In experimental myocardial infarction, higher PDE2 abundance 
improved ventricular function and may even prolong survival. 
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Methods  
For a detailed description of methods including surgical procedures see Online Supplement 
Material. 
Chronic isoproterenol administration: Isoproterenol (ISO, 30 μg/g/d, Sigma-Aldrich) was 
delivered to mice by subcutaneously implanted osmotic minipumps (Alzet, model 2002). 
Application of dobutamine, BAY 60-7550 and metoprolol for echocardiographic 
experiments: Anesthetized mice were analyzed by echocardiography first under basal 
conditions and then 5 min after the injection of dobutamine (DOBU, i.p., 10 mg/kg). When 
indicated, BAY (i.p., 3 mg/kg) was applied 10 min post DOBU injection, and after an 
additional period of 10 min cardiac function was again echocardiographically monitored. For 
metoprolol studies, doses from 1 to 100 mg/kg (i.p.) were cumulatively applied with 10 min 
intervals between injections and echocardiographic measurements. 
Generation of PDE2 transgenic mice: PDE2-TG mice were generated by using a plasmid 
containing the murine sequence of the splice variant PDE2A3 (NM_001008548.3). 
Expression was set under the control of the human -myosin heavy chain promoter to 
ensure cardiac specificity30. Transgenesis was achieved by pronucleus injection of linearized 
plasmids into isolated zygotes of a FVB/N donor strain. Successful transformation of the 
offspring was assessed by PCR and overexpression levels were determined by immunoblot 
analysis. Resulting founder lines were crossed into a C57Bl/6 background.  
ECG-telemetry recordings and arrhythmia provocation: ECGs were recorded in freely 
moving unrestrained mice. Arrhythmia provocation was performed by double injections of 
isoproterenol (ISO, i.p. 2 mg/kg) separated by an interval of 30 min; analysis was performed 
for 90 min after the first injection. 
Isolation of adult mouse ventricular myocytes: Adult mouse ventricular myocytes were 
isolated by Langendorff perfusion using a Ca2+-free Tyrode’s solution containing liberase as 
described previously31. 
 
cAMP measurements by FRET: Adult mouse ventricular myocytes mice were infected with 
an adenovirus encoding the Epac-SH187 cAMP FRET probe for 24 h32. Changes in cAMP 
levels were assessed by YFP/CFP emission ratios. 
 
Patch-Clamp studies: L-type Ca2+ currents (ICa,L) were recorded in the whole-cell 
configuration of the patch-clamp technique33.  
 
Ca2+ spark analysis: Ca2+ spark measurements were performed on a laser scanning 
confocal microscope (LSM 5 Pascal, Zeiss). Fluorescence images of Fluo-3 AM (10 μmol/L, 
Molecular Probes) loaded ventricular myocytes were recorded in the line-scan mode. 
Measurement of Ca2+ transients, sarcomere shortening, SR Ca2+ leak and load: Isolated 
mouse ventricular cardiomyocytes were loaded with 3 µmol/L Fura-2 AM (Invitrogen). 
Sarcomere shortening and Fura-2 ratio (measured at 512 nm upon excitation at 340 and 380 
nm) were simultaneously recorded using spectrofluorimeter coupled with a video detection 
system (IonOptix) as previously described33. Myocytes were electrically stimulated at a 
frequency of 0.5 Hz. 
Immunoblot analysis: Protein samples were prepared from pulverized ventricular 
myocardium and lyzed in a buffer containing 30 mmol/L Tris/HCl (pH 8.8), 5 mmol/L EDTA, 
30 mmol/L NaF, 3% SDS, and 10% glycerol. Samples were separated in denaturizing 
acrylamide gels and subsequently transferred onto nitrocellulose or PVDF membranes. After 
blocking the membranes with Roti®-block (Carl Roth) for 1 h, the incubation with anti-
calsequestrin (1:1,000, ThermoScientific), anti-SERCA2a, anti-PDE2 (each 1:200, Santa 
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Cruz), anti-pPLB-S16, anti-pPLB-T17, anti-PLB, anti-pRYR2-S2808, anti-pRYR2-S2814 
(each 1:5,000, Badrilla), and anti-RYR2 (1:2,000, Sigma-Aldrich) was carried out over night 
at 4°C. After incubation with appropriate secondary antibodies for 1 h, proteins were 
visualized by enhanced chemoluminescence (VersaDoc, Biorad) and quantified with Quantity 
One software (Biorad). 
Ligation of the anterior descending artery 
At the age of 10-14 weeks, mice were subjected to permanent ligation of the left anterior 
descending coronary artery (LAD) to induce myocardial infarction. After anesthesia was 
induced using 10% ketamine/ 2% xylazine i.p., the chest was opened between the third and 
the fourth rib. A 8−0 silk suture was used to occlude the LAD. Animals received 
buprenorphine (0.05–0.1 mg/kg, s.c.) for post-operative analgesia. ECG-telemetry recordings 
were performed for 2 weeks after LAD ligation. 
Statistics: Results are presented as mean±SEM. Data sets were compared by Student’s t-
test, one-way ANOVA followed by Newman Keuls multiple comparison test, two-way 
ANOVA, Fisher’s exact test or Pearson correlation according to the experimental setting. P 
values of less than 0.05 were considered statistically significant. 
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Results  
Consequences of pharmacological PDE2 inhibition on cardiac function in vivo 
To characterize the contribution of PDE2 to cardiac function under chronic β-AR stimulation 
in vivo, we subjected mice to ISO infusions (30 mg/kg/d for 7d) or NaCl (0.9%) as control. As 
expected, ISO treated animals developed prominent cardiac hypertrophy, indicated by an 
increase in left ventricular weight to body weight ratio from 3.6±0.2 to 4.7±0.1 mg/g (p<0.05, 
Suppl. Fig. 1). After chronic ISO treatment, the positive chronotropic and ionotropic effects of 
DOBU were abrogated, indicating desensitization of the β-ARs (Fig. 1). This was completely 
reversed by inhibition of PDE2 with BAY (3 mg/kg), restoring β-AR responsiveness to the 
level observed in the control group (Fig. 1). Interestingly, PDE2 inhibition also had an effect 
on control mice, almost doubling the impact of β-AR stimulation on heart rate over the 
average basal heart rate of 424±18 bpm from 95±29 to 170±23 bpm (Fig. 1B). The dosage of 
3 mg/kg was chosen according to recent publications regarding in vivo experiments in 
rodents34 and unpublished pharmacokinetic studies provided by BAYER. This restriction of 
PDE2 to chronotropic regulation under physiological conditions was supported by a study on 
beagle dogs treated with increasing doses of BAY (3, 10, and 30 mg/kg). In line with the 
murine model, the inhibition of PDE2 predominantly resulted in acceleration of heart rate (10 
mg/kg: +20%; 30 mg/kg: +28%, Suppl. Fig. 2A), while stroke volume (SV), cardiac output 
(CO) and systolic (BPs) as well as diastolic blood pressures (BPd) remained largely 
unchanged (Suppl. Fig. 2B). Taken together, the role of PDE2 seems restricted to heart rate 
regulation under physiological conditions, while its stress-induced upregulation contributes to 
the desensitization of both β-AR-induced increases in heart rate and contraction force. 
Effect of PDE2 overexpression on heart rate and cardiac function  
To gain insight into the consequences of higher cardiac PDE2 levels, we generated 
transgenic (TG) mouse lines which overexpress PDE2 about 6- to 15-fold specifically in 
cardiomyocytes (Fig. 2H; Suppl. Fig. 3, 4). The low expressing (6-fold) line TG-4808 did not 
show any overt phenotype (Suppl. Fig. 3). In contrast, the ~10-fold overexpressing line TG-
4320 (Fig. 2H) analyzed at 2 months displayed a substantial lower basal and dobutamine 
(DOBU)-stimulated maximal heart rate compared to wildtype (WT) with an average 
difference of 77±17 and 98±14 bpm, respectively (Fig. 2B). Basal contraction force measured 
as fractional area shortening (FAS) was higher in TG-4320 than in WT (37±1% vs. 32±1%), 
while maximal DOBU-stimulated contractility remained unaffected (80±3% in WT and 77±2% 
in PDE2-TG, Fig. 2A). In line with this, the lower heart rate combined with higher basal 
contraction produced a cardiac output virtually identical to that of WT controls (Fig. 2C). The 
higher contraction force in TG-4320 was not associated with cardiac hypertrophy as left 
ventricular weight to body weight ratio or heart weight to tibia length did not differ between 
WT and PDE2-TG mice (Fig. 2G, 3C). PDE2-TG displayed preserved susceptibility to β-AR 
blockade by metoprolol regarding the decrease both in heart rate and FAS with IC50 values 
that paralleled WT controls (Fig. 2D-F, Suppl. Fig. 5). Interestingly, while maximal doses of 
metoprolol (100 mg/kg) reduced heart rate to a similar extent in WT and PDE2-TG (332±15 
and 306±8 bpm, respectively), FAS of PDE2-TG was higher under βAR blockade compared 
to WT controls (31±2% in WT vs. 44±2% in PDE2-TG, Fig. 2D, F). The specific phenotype of 
lower HR with preserved cardiac performance was confirmed in a second independent 
transgenic line (TG-4811) with even higher overexpression levels (15-fold, Suppl. Fig. 4) 
excluding possible insertion artefacts. In accordance with recently published guidelines for 
transgenic mice35 the lower expressing TG-4320 was chosen for the following experiments 
and will hence be referred to as PDE2-TG or TG.  
Next, we analyzed the effects of PDE2 abundance on cardiac morphology and performance 
throughout most of the animals’ life span including elderly mice. Notably, during 18 months of 
serial echocardiography, low heart rate and higher cardiac performance were preserved with 
no indication of functional decline, maladaptive remodeling or premature death (Fig. 3). The 
prominent impact on basal heart rate prompted us to investigate the effect of PDE2 on heart 
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rate regulation by telemetric ECG recordings in unrestrained, freely moving mice. Circadian 
analysis over the course of 24 h confirmed significantly lower heart rates in PDE2-TG 
animals during low activity daytime (105±17 bpm) as well as high activity nighttime (90±24 
bpm, Fig. 4A, B and Suppl. Fig. 6A, B). Accordingly, analysis of the respective RR intervals 
recorded for 24 h showed longer average intervals in PDE2-TG demonstrated by a rightward 
shift of the Gaussian distribution curve (Fig. 4C). The difference in RR pattern was further 
confirmed by Poincaré analysis (Suppl. Fig. 6C, D). Notably, the broadening of the RR 
distribution as well as the significantly higher standard deviation from average RR-intervals 
indicate higher heart rate variability in PDE2-TG compared to WT animals (Fig. 4D). Thus, 
overexpression of PDE2 recapitulates the classical shift in sympathetic/parasympathetic 
balance as observed during an increased parasympathetic control of heart rate regulation36. 
However, PDE2-TG displayed the same relation of heart rate and physical activity as WT 
littermates, indicating preserved chronotropic competence (Fig. 4E). Basal heart rate 
reduction with maintained autonomic control has been allocated to a decrease in 
hyperpolarization-activated cyclic nucleotide-gated (HCN) channels activity37. Therefore we 
investigated the impact of HCN-blocker ivabradine (IVA; i.p. 5 µg/g) on heart beat frequency 
(Fig. 4F, Suppl. Fig. 6E). WT and TG animals showed similar susceptibility to IVA treatment 
displaying no significant difference in either lowest heart rate (348±23 and 319±17 bpm, 
respectively) or average heart rate reduction (158±10 bpm for WT and 128±14 for TG). 
Impact of PDE2 overexpression on cAMP levels and Ca2+ cycling 
To study the cellular mechanisms involved in PDE2 action, we investigated how PDE2 
overexpression affects intracellular cAMP levels ([cAMP]i). For that, we assessed real time 
changes in β-AR-induced [cAMP]i by FRET measurements in isolated ventricular myocytes 
infected with an adenovirus expressing the FRET-based cAMP probe Epac-SH187 32. The 
response to a 15 s application of ISO (30 nmol/L) was markedly blunted in PDE2-TG 
myocytes which showed an average change over basal of 17% compared to an average of 
120% displayed by WT animals (Fig. 5A). 
Next, we analyzed the consequences of the reduced accumulation of [cAMP]i on cellular 
Ca2+ handling in PDE2-TG mice. In line with previous publications, PDE2 overexpression 
markedly attenuated the β-AR induced increase in ICa,L from 35% in WT to 8% in PDE2-TG 
(Fig. 5B), while basal ICa,L amplitude remained unaffected (data not shown). This effect was 
fully reversed by PDE2 inhibition with BAY (Fig. 5C). Accordingly, Ca2+ transient and 
contractility analysis in field stimulated isolated ventricular myocytes revealed an attenuation 
of the β-AR response to ISO, while basal contractility and Ca2+ transients were similar 
between WT and PDE2-TG mice (Suppl. Fig. 7). SR Ca2+ load and fractional release were 
evaluated during the SR leak protocol (see below) by rapid application of 10 mmol/L caffeine. 
As expected, SR Ca2+ load as well as the fraction of released Ca2+ from the SR during 
systole significantly increased in WT derived ventricular myocytes after β-AR stimulation. In 
contrast, the ISO-induced increase in fractional SR Ca2+ release was absent in PDE2-TG, 
while SR Ca2+ content was not affected neither under basal nor stimulated conditions (Fig. 
5D, E). This observation is in line with the lower β-AR response of systolic Ca2+ amplitude 
and force development measured in myocytes from PDE2-TG (Suppl. Fig. 7). 
Arrhythmia provocation  
To test the effect of greater PDE2 abundance under acute β-AR stress, animals received two 
injections of ISO (2 mg/kg) separated by an interval of 30 min38. As expected from 
echocardiographic analysis (Fig. 2B) and heart rate/activity correlation (Fig. 4E), PDE2-TG 
displayed a lower maximal heart rate upon β-AR stimulation (693±9 bpm in WT vs. 610±5 
bpm in PDE2-TG), while chronotropic adaptation, i.e. absolute increase over basal heart 
rate, was maintained (157±18 bpm and 154±11 bpm, respectively, Fig. 6A, B). ECG was 
monitored for arrhythmic events such as ventricular extra systoles (VES), salvos and 
ventricular tachycardia (VT) over a period of 90 min after the first injection. All animals tested 
developed VES with frequency of occurrence increasing starting approximately 15 min after 
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the second injection of ISO (Suppl. Fig. 8A). The total number of VES was significantly lower 
in PDE2-TG (73±12 in WT vs. 30±9 in PDE2-TG, Fig. 5C). Importantly, only 1 out of 7 TG 
animals displayed severe arrhythmic events in form of VTs, while VTs were common 
incidents in WT animals where 6 out of 7 animals were affected (Fig. 6D, E). This finding was 
further confirmed in vitro where isolated WT ventricular myocytes exposed to ISO showed 
frequent occurrences of spontaneous Ca2+ waves (sCaW) which were abrogated in myocytes 
isolated from PDE2-TG mice (Fig. 6F, G). 
Ca2 leak and Ca2+ handling proteins 
Since ISO-induced arrhythmias are to a large extent caused by an increased diastolic Ca2+ 
leak from the sarcoplasmic reticulum (SR) via the ryanodine receptor (RYR2)39-41, analysis of 
Ca2+ sparks was conducted to estimate Ca2+ leakage. PDE2-TG animals revealed a trend to 
a lower number of sparks under basal conditions and a complete abrogation of the increase 
in spark frequency after application of ISO, indicating the likely underlying cause of the 
reduced arrhythmia burden of PDE2-TG mice after ISO injection (Fig. 7A, B). This was 
further confirmed by assessing the SR Ca2+ leak as the difference between the Fura-2 ratio 
with and without RYR2 blocker tetracaine (1 mmol/L), using a 0Na+/0Ca2+ solution to prevent 
Ca2+ extrusion by the Na+/Ca2+ exchanger (Suppl. Fig. 9).  
To explore the molecular mechanisms of a reduced Ca2+ leak, we performed immunoblot 
analysis of key Ca2+ handling proteins (Fig. 7C-G). Consistent with the preserved SR Ca2+ 
load in PDE2-TG mice (Fig. 5D), we did not find differences between WT and PDE2-TG mice 
in regard to the expression of SERCA2a, PLB or RYR2. PLB phosphorylation was 
significantly reduced at S16 and milder also at T17. Most strikingly, we found a reduction of 
RYR2 receptor phosphorylation at the described Ca2+/calmodulin-dependent kinase II 
(CaMKII) phosphorylation site, S2814, which has been linked to diastolic Ca2+ leakage, but 
not at the putative PKA site S2808.  
Arrhythmia development and cardiac function after myocardial infarction 
To induce myocardial infarction (MI), mice were subjected to ligation of the left anterior 
descending artery (LAD). While infarct size was similar in both groups (Fig. 8C), PDE2-TG 
were markedly protected against ventricular failure with an ejection fraction of 47±5% 
compared to 31±4% in WT (Fig. 8A, B) at 14d after MI. The overall VT incidence was only 
slightly and not significantly lower in PDE2 TG than in WT: 62.5% of the WT and 53.3% of 
PDE2-TG developed VTs in the first 40 h following MI (Fig. 8E). However, only 30% of WT 
with VTs survived the first 7d, whereas none of the PDE2-TG with VTs suffered from an early 
death (Fig. 8F). Moreover, all early WT deaths were preceded by VTs, while PDE2-TG did 
not show this correlation (Fig. 8G). Further analysis of WT and PDE2-TG VT quality 
suggested a tendency towards long VTs (>20s) in WT animals with early deaths (3 out of 7), 
which occurred neither in WT survivors nor in PDE2-TG (Suppl. Fig. 10, Fig. 8H). Overall, 
over 86% of PDE2-TG survived the early phase post MI, while only 56% of WT animals 
endured more than 7d (Fig. 8D, p=0.06). No further deaths occurred in either group between 
day 8 and day 14 (endpoint of intervention). 
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Discussion  
Myocardial PDE2 is upregulated in human as well as in experimental HF but its physiological 
and pathological role in the heart remained unknown. Here, we show that heart rate 
regulation is the predominant physiological role of PDE2. Specific inhibition of PDE2 in dogs 
and mice led to an exclusive increase in heart rate, while overexpression of PDE2 resulted in 
its decrease. Under chronic β-AR activation, however, PDE2 contributes to myocardial β-AR 
desensitization, protecting the heart from excessive sympathetic stress. Moreover, under 
acute β-adrenergic stress, higher PDE2 abundance effectively protects against ventricular 
arrhythmia without compromising contractile performance in vivo. In the setting of MI, PDE2 
TG showed improved ventricular function compared to WT. 
Role of PDE2 in heart rate regulation  
The modern concept of heartbeat initiation is based on the mutual interplay between ion 
channels of the cell membrane (“membrane clock”) and cellular Ca2+ cycling (“Ca2+ clock”)42, 
43. The most prominent targets of sympathetic heart rate modulation are the funny current (If), 
mediated by cAMP-dependent regulation of HCN channels and PKA-dependent 
phosphorylation of L-type Ca2+ channels (LTCC) as well as of SR Ca2+ cycling proteins44. So 
far, PDE2 has been shown to contribute to myocardial Ca2+ cycling by modulating ICa,L not 
only in ventricular, but also in atrial and sinoatrial nodal cells23, 24, 45. These findings are 
consistent with the attenuated β-AR responsiveness regarding ICa,L and SR Ca2+ release 
observed in PDE2-TG derived ventricular myocytes. Moreover, the close interplay between 
ICa,L, RYR2-mediated Ca2+ release and SERCA/PLB-dependent filling of the SR suggests that 
PDE2 is involved in the regulation of the Ca2+ clock43. However, while in the ventricular 
myocardium in vivo contraction force was unaffected in PDE2-TG, PDE2-TG exhibited lower 
basal as well as maximal heart rates, but retained β-AR induced control of pacemaker 
activity. This particular chronotropic phenotype has remarkable parallels with a cardiac 
cAMP-binding deficient HCN4 mutation analyzed in mice and humans46, 37. Notably, while 
HCN-blockade with IVA had no effect in mice expressing the mutated channel46, PDE2-TG 
mice were still sensitive to IVA treatment indicating a remaining contribution of If to basal 
heart rate regulation. This study shows for the first time, that PDE2 is a major player in heart 
rate regulation in vivo, most likely by affecting both membrane and Ca2+ clock. 
Role of PDE2 in propensity to arrhythmia and in contractility 
There is substantial evidence that generation of delayed afterdepolarizations due to 
increased diastolic Ca2+ leak from the SR via RYR2 and the subsequent depolarizing activity 
of the Na+/Ca2+ exchanger (NCX) is the main underlying mechanism for triggered 
arrhythmias47. A central role in this dysfunction of Ca2+ cycling has been attributed to the 
phosphorylation of RYR2 at the CaMKII site S2814 and the associated facilitation of diastolic 
Ca2+-release40, 41, 48. Our conclusion that PDE2-TG are less susceptible to arrhythmia 
provocation induced by acute β-AR stimulation due to a significantly lower Ca2+-spark 
frequency as well as lower RYR2-S2814 phosphorylation fits well to this model. At the 
cardiomyocyte level, efficacy of β-AR-induced increase in sarcomere shortening was 
significantly attenuated, as were efficacy and potency of β-AR-induced stimulation of Ca2+-
transients. Notably, at baseline and at low ISO concentrations, contractile parameters were 
normal (Suppl. Fig. 8). However, the in vitro findings regarding force development did not 
entirely recapitulate the actual phenotype of PDE2-TG mice. Our in vivo data clearly 
demonstrate that PDE2 overexpression was associated with a normal contractile reserve and 
rather improved contraction force. This was even maintained when heart rate was reduced to 
an identical level (332±15 vs. 306±8 bpm) induced by acute β-blockade (Fig. 2 D-F) 
indicating that the lower basal heart rate per se e.g. via augmented filling in diastole cannot 
completely explain the hypercontractile phenotype. Despite lower PLB-phosphorylation, SR 
load did not appear affected in PDE2-TG. Longer diastolic intervals and the reduced Ca2+ 
leak may therefore be sufficient for maintaining adequate SR Ca2+ filling and preservation of 
cardiac function in vivo, even in the presence of reduced SERCA activity48. In summary, 
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PDE2 overexpression offers a potential dual protection by limiting heart rate without affecting 
chronotropic adaptation and by attenuating ventricular SR Ca2+-release with the benefit of 
lower arrhythmia susceptibility. The effect of PDE2 overexpression is therefore similar to β-
blocker treatment but without depression of contractile performance. 
PDE2 in cardiac remodeling 
A very recent publication proposed that in context of cardiac remodeling processes, chronic 
inhibition of PDE2 leads to a reduction of pathological hypertrophic growth49. While this 
contradicts our earlier finding that adenoviral overexpression of PDE2 antagonizes β-AR 
induced cellular hypertrophy 29, 50, we observed a small but not significant increase in cardiac 
size in PDE2-TG mice as compared to WT (Fig. 2G, 3C). Therefore, we cannot completely 
rule out a minor increase of heart size due to PDE2 overexpression. Consistently, heart 
weight was also ~10% higher in PDE2-TG mice after MI compared to WT (Suppl. Fig. 11). 
However, preservation of cardiac function and size up to an advanced age (Fig. 3) strongly 
argues against pathological hypertrophy. Moreover, we offer proof that high abundance of 
PDE2 significantly protects against acute and chronic β-AR stress and maintains contractile 
function after MI.  
Potential limitations  
A general limitation of transgenic “overexpressors” is potential spill over within subcellular 
compartments, where the protein of interest may be not physiologically located. This is even 
more critical when examining PDEs, which control highly compartmentalized cAMP pools 
and redistribution phenomena under pathological conditions have been reported51, 52. Despite 
designing our experiments following general recommendations for state-of-the-art 
phenotyping of transgenic mice35, we are not able to fully exclude artificial compartmentation 
effects. However, the specificity of the phenotype and its striking similarities to in vivo studies 
of endogenous PDE2 from mice and larger animals offers a valid approach for analyzing the 
pathophysiological role of PDE2 in heart function. A second limitation is that the role played 
by each PDE isoform varies among mammalian species53, 54 and accordingly, our results may 
not recapitulate the situation in humans in all details.  
Clinical perspective: PDE2 as a downstream target of cGMP pools 
The current therapeutic strategies for HF and prevention of sudden cardiac death are only 
moderately effective. Despite all efforts, a lack of understanding of the pathophysiological 
mechanisms underlying HF and arrhythmias has hindered the development of more 
effective, rational therapeutic approaches. Recently, the publication of the PARADIGM-HF 
trial, which demonstrated the successful introduction of the compound LCZ696 (a 
combination of a standard Angiotesin-II-receptor-1 blocker and an inhibitor of the NP-
degrading enzyme neprilysin), has once again shifted the enhancement of cGMP-signaling 
into the focus of HF therapy. One remarkable result of the study was a significant protection 
from sudden cardiac death55, 56. The importance of the NP signaling pathway was further 
emphasized in a study by the Kass group showing that the inhibition of cGMP-degrading 
PDE9 protects against HF progression by specifically targeting the ANP/BNP-coupled cGMP 
pool16, 57. PDE2 is a central component of the cGMP/cAMP crosstalk and as our study 
demonstrates effectively protects against ventricular arrhythmia during excessive 
sympathetic stress and improved ventricular function after a severe cardiac insult. It may 
therefore constitute an up to now unconsidered link between ANP/BNP-coupled cGMP 
enhancement and the protection against toxic sympathetic effects by acting as a cGMP 
controlled intracellular sympathetic blockade. Thus, PDE2 is worth being considered a key 
element in recent encouraging therapeutic approaches and accordingly its direct activation 
may offer an alternative strategy in a promising new field of HF therapy. 
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Figure 1. PDE2 regulates heart rate and blunts β-AR-induced inotropy in animals chronically 
treated with ISO. Effect of PDE2 inhibition in mice exposed to chronic ISO infusions for 7 d 
(30 mg/kg*d) or treated with vehicle (0.9% NaCl). Animals were anaesthetized and monitored 
by echocardiography under basal conditions, 2-7 min after dobutamine (10 mg/kg i.p., 
DOBU) injection and 10 min after application of the PDE2 inhibitor BAY 60-7550 (3 mg/kg 
i.p., BAY) on top of DOBU (DOBU+BAY). (A) Fractional area shortening (FAS). (B) Heart 
rate (HR); n=7-8 for each group. Statistical significance was determined by one-way ANOVA 
followed by Newman-Keuls multiple comparison test. *p<0.05 vs. NaCl, #p<0.05 vs. 
respective basal, and $p<0.05 vs. DOBU. 
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Figure 2. Higher basal contractility and lower heart rate in PDE2-TG. Echocardiographic 
determination of fractional area shortening (FAS, A), heart rate cardiac (HR, B) and output 
(CO, C), and in anaesthetized 2 month old mice. Animals were treated with 10 mg/kg 
dobutamine (DOBU, i.p.) 2 min prior to measurements when indicated; n=7-9 for each group. 
Effect of metoprolol (100 mg/kg, i.p.) on (D) FAS and (E) HR in anaesthetized animals. (G) 
Correlation between the reduction of FAS and HR in the presence of increasing metoprolol 
doses (METO 0, 1, 3, 10, 30 and 100 mg/kg); n=5 for each group. (G) Left ventricular weight 
(LVW) calculated from the echocardiographic data and normalized to tibia length. (H) 
Lysates prepared from ventricular myocardium were analyzed by immunoblot with the 
indicated specific antibodies. PDE2 expression was normalized to calsequestrin (CSQ) and 
given relative to WT. (E) Representative immunoblots and (F) quantification; n=7-9 for each 
group. Statistical significance was determined by One-way ANOVA followed by Newman-
Keuls multiple comparison test (A, B, D, E) and Student’s t-test to compare the two 
genotypes on basal level (A-E, G,H). *p<0.05 vs. WT, #p<0.05 vs. respective basal. 
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Figure 3. Preserved phenotype of higher basal contractility and lower heart rate in elderly 
PDE2-TG. Echocardiographic determination of fractional area shortening (FAS, A), and heart 
rate (HR, B) in anaesthetized 3-18 month old mice. (C) Left ventricular weight (LVW) was 
calculated from the echocardiographic data and normalized to body weight (BW); n=6 for 
each group. Statistical significance was determined by Two-way ANOVA. *p<0.05 vs. WT. 
(D) Longevity study of WT (n=12) and PDE2-TG (n=16). The study was terminated after 38 
months. Average life span of WT=24 and PDE2-TG=29 months. 
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Figure 4. PDE2 transgenic mice show higher heart rate variability and normal chronotropic 
adaptation. Animals (n=4-5 per genotype) were monitored by ECG-telemetry for a period of 
72 h to calculate average changes in heart rate (HR) and heart rate variability of a 24 h cycle. 
Frequencies and activity were tracked as averages of 1 min intervals. (A) Average circadian 
changes in heart rate over a period of 24 h. (B) Average heart rate during day and night 
periods. (C) Heart rate variability given as occurrence of RR-intervals during one 24 h 
recording with Gaussian distribution curve calculated for each group. (D) Standard derivation 
of average RR-intervals (SDNN). (E) Correlation between heart rate and activity. (F) Average 
HR over a period of 20 min prior (0-20 min) and after ivabradine (IVA, 5 mg/kg, i.p.) injection 
(10-30 min). Statistical significance was determined by one-way ANOVA followed by 
Newman-Keuls multiple comparison test and Student’s t-test to compare the two genotypes 
(D). *p<0.05 vs. WT, #p<0.05 vs. day (B) or respective basal (F). 
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Figure 5. Ventricular myocytes from PDE2-TG mice show reduced β-AR-response, but 
normal SR Ca2+ load. (A) Normalized average time course of [cAMP]i in response to a 15 s 
application of ISO (30 nmol/L) in WT and PDE2-TG ventricular myocytes infected with an 
adenovirus expressing the FRET-based cAMP probe Epac-SH187; n=3 animals/genotype with 
11-13 cell in each group. (B, C) Normalized average time course of ICa,L amplitude following 
ISO pulse stimulation (30 nmol/L, 15 s) in the absence (B) or presence (C) of PDE2 inhibitor 
BAY 60-7550 (100 nmol/L). The cells were depolarized every 8 s from -50 to 0 mV during 
400 ms; n=3 animals/genotype with 10-19 cell in each group. (D) Mean amplitude of SR Ca2+ 
load in the presence or absence of ISO measured as the change in Fura-2 ratio after rapid 
application of caffeine (10 mmol/L). (E, F) SR Ca2+ load and fractional release measured in 
Fura-2 loaded adult mouse ventricular myocytes paced at 1 Hz, in the presence or absence 
of ISO (100 nmol/L) (E) Mean fractional Ca2+ release in control or ISO calculated as the ratio 
of Ca2+ transient amplitude divided by caffeine-induced response; n=2-3 animals/genotype 
with 7-11 cells in each group. Statistical significance was determined by One-way ANOVA 
followed by Newman-Keuls multiple comparison test. *p<0.05 vs. WT, #p<0.05 vs. respective 
basal. 
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Figure 6. PDE2 transgenic mice show the same absolute increase in heart rate after β-AR 
stimulation, but lower susceptibility to arrhythmic events. Heart rate was monitored after 
double ISO injection (2 mg/kg, i.p.; time interval between injections: 30 min) and analyzed for 
ventricular extra systoles (VES), salvos and ventricular tachycardia (VT) over a period of 90 
min after the first application; n=7. (A) ISO-induced increase in heat rate (HR) calculated as 
an average of 5 s intervals. (B) Absolute increase over basal heart rate. (C) Total number of 
VES per animal. (D) Number of animals with VTs; n=7. (E) Representative trace of a WT 
animal showing VTs; with bigeminy (alternations of sinus beat and VES) before onset of VT. 
(F, G) Effect of PDE2 overexpression on spontaneous Ca2+ waves (sCaW) in mouse 
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ventricular cells. (F) Representative traces of Ca2+ transients in Fura-2 loaded mouse 
ventricular cells isolated from WT or PDE2-TG mice paced at 0.5 Hz in the presence of 100 
nmol/L ISO. (G) Percent of cells with sCaW in WT and PDE2-TG mice after ISO-treatment; 
n=3-4 animals/genotype with a total of 16-22 cells in each group. Statistical significance was 
determined by One-way ANOVA followed by Newman-Keuls multiple comparison test (A), 
Student’s t-test to compare the two genotypes (B, C) and Fisher’s exact test (D, G) to 
compare occurrence of events. *p<0.05 vs. WT, #p<0.05 vs. respective basal. 
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Figure 7. PDE2 transgenic mice show reduction in Ca2+ leak and phosphorylation of Ca2+ 
handling SR proteins in ventricular myocardium. (A, B) Ventricular myocytes were loaded 
with Fluo-3 AM and monitored for Ca2+-sparks by laser scanning confocal microscopy under 
basal conditions and after stimulation with 100 nmol/L ISO. (A) Quantification of Ca2+-spark 
frequency (CaSpF) normalized to cell width and scan rate. (B) Representative original 
recordings, n=4 animals/genotype. (C-G) Lysates prepared from ventricular myocardium 
were analyzed by immunoblot with the indicated specific antibodies. Protein phosphorylation 
was normalized to the respective total protein. (C-F) Quantification and (G) representative 
immunoblots showing additionally the expression levels of sarcolemma Ca2+ ATPase 2a 
(SERCA2a) and calsequestrin (CSQ); n=7-8 for each group. Statistical significance was 
determined by One-way ANOVA followed by Newman-Keuls multiple comparison test and 
Student’s t-test to compare the two genotypes. *p<0.05 vs. WT, #p<0.05 vs. respective basal. 
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Figure 8. PDE2-TG are protected from early death, sustained arrhythmias and decline of 
heart function after myocardial infarct (MI). (A) Ejection fraction calculated from 
echocardiographic analysis prior MI (baseline) and at day 14 post MI. (B) Representative M-
Mode trace from infarcted area taken 14 d post MI. (C) Left panel: Representative Sirius Red 
staining of heart sections prepared from surviving animals at day 14; right panel: 
quantification of infarct size given as % of total tissue area. (D) % of surviving animals. Study 
was terminated 14 d post MI. (E, F, G) Analysis of ventricular tachycardia (VT) during the first 
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40 h post MI and association with early death events. (FH) Representative ECG-traces 
showing a 17 s lasting VT in WT and 4 s in TG animals. Statistical significance was 
determined by One-way ANOVA followed by Newman-Keuls multiple comparison test (A), 
Long rank test (B), and Fischer’s exact test (F, G). *p<0.05 vs. WT, #p<0.05 vs. respective 
baseline. 
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Detailed Methods 
All experiments were carried out according to the European Community guiding principles in 
the care and use of animals (2010/63/UE, 22 september 2010), the local Ethics Committee 
(CREEA Ile-de-France Sud) guidelines and the French decree n° 2013-118, 1st February 
2013 on the protection of animals used for scientific purposes (JORF n°0032, 7 February 
2013 p2199, text n° 24). Authorizations were obtained from the Niedersächsisches 
Landesamt für Verbraucherschutz und Lebensmittelsicherheit (Germany) and Ministère 
Français de l'Agriculture, de l’Agroalimentaire et de la Forêt (agreement N°B 92-019-01). 
 
Application of BAY 60-7550 for cardiovascular analysis, canine animal model 
Evaluation of hemodynamic parameters was performed in beagle dogs according to GLP 
requirements using a dog model described earlier1. Both male and female animals were used 
at an age of 1 to 5.5 years and 9.5 to 16 kg body weight. Briefly, 12 Beagle dogs were 
subjected to general neuroleptic anesthesia (droperidol + fentanyl) and mechanical 
ventilation with nitrous oxide/oxygen (1:3). Administration formulations of BAY 60-7550 
(BAY) were prepared in ethanol/polyethylene glycol 400 (1:9 v/v) and administered 
intraduodenally (i.d.) with an administration volume of 1-2 ml/kg in a dose range of 3, 10, and 
30 mg/kg (n=3 dogs per group). Three control animals received the vehicle only. Dogs were 
instrumented with a Millar tip catheter placed into the abdominal aorta for measurement of 
systemic arterial blood pressure. A second Millar catheter equipped with a pressure and a 
velocity sensor was introduced into the heart via the left carotid artery. The pressure sensor 
was located within the left ventricle, the velocity sensor located in the ascending aorta to 
allow the measurement of stroke volume, left ventricular pressure (LVP) and the 
determination of left ventricular pressure rise (LV dP/dt), a surrogate for heart contractility. 
Heart rate was determined by ECG. Cardiac output (CO) and total peripheral resistance were 
calculated from stroke volume, heart rate and mean arterial blood pressure. At predefined 
time points at baseline and up to 240 min after administration, cardiovascular parameters 
were collected, stored and evaluated using P3 Plus Ponemah software (DSI). 
 
Chronic isoproterenol administration 
Isoproterenol (ISO, Sigma-Aldrich) was delivered to mice by subcutaneously implanted 
osmotic minipumps (Alzet, model 2002) that released ISO solved in 0.9% NaCl at a dose of 
30 μg/g/d2. Anesthesia was performed with isoflurane (1.5% v/v). After 7 days, cardiac 
function was monitored by echocardiography. The mice used for this study were 2 month old 
littermates with a FVB/N background. Groups were age and sex matched. 
 
Echocardiography 
Animals were kept under light temperature and ECG-controlled anesthesia (isoflurane, 1.5% 
v/v or pentobarbital 35 mg/kg body weight (i.p.)) during the whole procedure. 
Echocardiography images (Vevo 770® System or 2100® System (MI), Visual Sonics Inc.) 
were obtained in a parasternal long and a short axis view at midpapillary and apical 
(representative M-mode pictures, MI) muscle level at a frame rate of 60 Hz. Long axis 
images were used to measure left ventricle length (L) during end-diastole (d) and end-systole 
(s). The thickness of the anterior (AWTh) and posterior wall (PWTh), the left ventricular 
diameter (LVD), the epicardial (EpiA) and endocardial (EndoA) area of the left ventricular 
cavity were obtained in the short axis or long axis (MI) view during d and s stages. 
Parameters were calculated as follows: %Fractional area shortening (%FAS) = (EndoAd – 
EndAs)/EndAd x 100; systolic volume (SV) = 5/6 x (EndoAd x Ld – EndoAs x Ls); cardiac 
output CO=SV x HR/1000; left ventricular weight (LVW) = 1.05 x 5/6 x [EpiAs x (Ls + (AWThs 
+ PWThs)/2)) – EndoAs x Ls], where 1.05 is the specific gravity of muscle. %Ejection fraction 
= 100* ((7.0 / (2.4 + average diastolic diameter)* (average diastolic diameter)3) – (7.0 / (2.4 + 
average systolic diameter) * (average systolic diameter)3) / ((7.0 / (2.4 + average diastolic 
diameter )* (average diastolic diameter)3). In MI, measurements were performed before and 
two weeks after left anterior descending coronary artery ligation. 
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Longevity study 
Animals were kept under standard housing conditions until either natural death or any severe 
illness occurred (e.g. tumor growth, colic, age related decay etc.). Animals, which fell sick 
during the study were euthanized according to animal care guidelines to avoid unnecessary 
pain and counted as a naturally death event. The study was terminated after 38 months with 
3 still living individuals. Groups were age and sex matched. 
Implantation of ECG transmitters  
Mice were anaesthetized with isoflurane (2% v/v) via mask ventilation and placed on a 
warming plate (37°). After the skin of the anterior thoracic region was depilated and 
disinfected, a 2 cm long median incision of the thoracic skin was made. The underlying tissue 
was prepared in order to create subcutaneous space for the ECG-transmitter (Data Sciences 
International, ETA-F10) and the electrodes. Afterwards, the ECG-transmitter was placed 
subcutaneously to the back of the mouse, the negative electrode was fixed to the right 
pectoralis fascia and the positive electrode was fixed 1 cm left to the xiphoid. The wound was 
closed using resorbable sutures. Alternatively, the transmitters were implanted into the 
peritoneal cavity. Buprenorphine 0.05 mg/kg s.c. once before starting the surgical procedure 
and metamizol 300 mg/kg p.o. from 2 days before to 7 days after the surgical procedure 
were used for intra- and postoperative analgesia. Recordings were started after a recovery 
time of at least two weeks post subcutaneous implantation of the telemetric transmitter). 
Recording and analysis parameters were set according to the manufacturer’s instructions 
using P3 Plus software (DSI) or LabChart software (Chart 5.4, AD Instruments) and to 
conventional arrhythmia/frequency analysis guidelines3-5. Heart rate, activity and RR-intervals 
are given as either an average of 1 min or of 5 s intervals. Details are specified in the 
respective figure legends. 
 
Isolation of adult mouse cardiomyocytes 
Ventricular myocytes were obtained from 10 to 14 week old male mice. Animals were 
anesthetized by intraperitoneal injection of pentothal (150 mg/kg), and the heart was quickly 
removed and placed into cold Ca2+-free Tyrode’s solution containing (in mmol/L): NaCl 113, 
KCl 4.7, MgSO4 4, KH2PO4 0.6, NaH2PO4 0.6, BDM 10, NaHCO3 1.6, HEPES 10, Taurine 30, 
D-glucose 20, adjusted to pH 7.4. The ascending aorta was cannulated and the heart was 
perfused with oxygenated Ca2+-free Tyrode’s solution at 37°C during 4 min. For enzymatic 
dissociation, the heart was perfused with Ca2+-free Tyrode’s solution containing liberase TM 
research grade (Roche Diagnostics) for 10 min at 37°C. Then the heart was removed and 
placed into a dish containing Tyrode’s solution supplemented with 0.2 mmol/L CaCl2 and 5 
mg/ml BSA (Sigma-Aldrich). The ventricles were separated from the atria, cut into small 
pieces, and triturated with a pipette to disperse the myocytes. Ventricular myocytes were 
filtered on gauze and allowed to sediment by gravity for 10 min. The supernatant was 
removed and cells were suspended in Tyrode’s solution supplemented with 0.5 mmol/L 
CaCl2 and 5 mg/ml BSA. The procedure was repeated once and cells were suspended in 
Tyrode’s solution with 1 mmol/L CaCl2. Freshly isolated ventricular myocytes were plated in 
35 mm culture dishes coated with laminin (10 µg/ml) and stored at room temperature until 
use6. 
 
cAMP measurements by FRET 
Adult mouse ventricular myocytes isolated from WT or PDE2-TG mice were infected with an 
adenovirus encoding the Epac-SH187 cAMP FRET probe for 24 h (kindly provided by Dr. Kees 
Jalink, Cancer Institute, Amsterdam, The Netherlands)7. Thereafter, the cells were washed 
once and maintained in a physiological buffer containing (in mmol/L): NaCl 144, KCl 5.4, 
CaCl2 1.8, MgCl2 1.8, and HEPES 20, pH 7.4 at room temperature. Images were captured 
every 5 s using the ×40 oil immersion objective of an inverted microscope (Nikon) connected 
to a Cool SNAP HQ2 camera (Photometrics) controlled by the Metafluor software (Molecular 
Devices). Cyan Fluorescent Protein (CFP) was excited for 300 ms by a Xenon lamp (Nikon) 
using a 440/20BP filter and a 455LP dichroic mirror. Dual-emission imaging of CFP and 
Yellow Fluorescent Protein (YFP) was performed using a Dual-View emission splitter 
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equipped with a 510 LP dichroic mirror and BP filters 480/30 and 535/25 nm, respectively. 
The YFP/CFP emission ratio upon 436 nm excitation (filters YFP 535 ± 15 nm, CFP 480 ± 20 
nm) was measured. After each measurement, emission values were corrected for 
bleedthrough of CFP into the YFP channel. The imaging data was analyzed with Excel. All 
experiments were performed at room temperature. 
 
ICa,L measurements  
The whole-cell configuration of the patch-clamp technique was used to record ICa,L. Pipette 
resistance was between 1–2 MΩ when filled with internal solution containing (in mmol/L): 
CsCl 118, EGTA 5, MgCl2 4, sodium phosphocreatine 5, Na2ATP 3.1, Na2GTP 0.42, CaCl2 
0.062 (pCa 8.5), HEPES 10, adjusted to pH 7.3 with CsOH. Extracellular Cs+-Ringer solution 
contained (in mmol/L): CaCl2 1.8, MgCl2 1.8, NaCl 107.1, CsCl 20, NaHCO3 4, NaH2PO4 0.8, 
D-glucose 5, sodium pyruvate 5, HEPES 10, adjusted to pH 7.4 with NaOH. For ICa,L 
measurement, the cells were depolarized every 8 s from -50 to 0 mV for 400 ms and the 
maximal amplitude of whole-cell ICa,L was measured as previously described8. The use of -50 
mV as holding potential allowed the inactivation of voltage dependent sodium currents. K+ 
currents were blocked by replacing all K+ ions with external and internal Cs+. Currents were 
not compensated for capacitance and leak currents. All experiments were performed at room 
temperature. 
 
Measurements of Ca2+ transients, sarcomere shortening, SR Ca2+ leak and load 
All experiments were performed at room temperature within 6 h after cell isolation. Isolated 
mouse ventricular cardiomyocytes were loaded with 3 µmol/L Fura-2 AM (Invitrogen) for 15 
min in Ringer’s solution containing (in mmol/L): KCl 5.4; NaCl 121.6; Na-pyruvate 5; NaHCO3 
4.013; NaH2PO4 0.8; CaCl2 1.0; MgCl2 1.8; glucose 5 and HEPES 10 (pH 7,4 with NaOH). 
Sarcomere shortening and Fura-2 ratio (measured at 512 nm upon excitation at 340 and 380 
nm) were simultaneously recorded in Ringer’s solution, using a double excitation 
spectrofluorimeter coupled with a video detection system (IonOptix, Milton, MA, USA). 
Myocytes were electrically stimulated with biphasic field pulses (5 V, 4 ms) at a frequency of 
0.5 Hz as previously described9. Because arrhythmias depend on the initial quality of cells, 
cardiomyocytes exhibiting spontaneous Ca2+ waves (sCaW) when perfused with control 
Ringer solution were discarded.  
SR Ca2+ leak and load were measured according to a dedicated protocol10. Fura-2 loaded 
ventricular myocytes were paced by field stimulation at 0.5 Hz in normal Ringer’s for few 
minutes until cellular Ca2+ transients reached a steady state. Directly after the last pulse, 
normal Ringer’s was substituted for 30 s by a 0Na+/0Ca2+ Ringer’s in which Na+ was replaced 
by Li+ and supplemented with 10 mmol/L EGTA. This condition allowed measuring 
intracellular Ca2+ levels in a closed system without trans-sarcolemmal Ca2+ fluxes. Then, the 
cell was switched back to normal Ringer’s and paced at 0.5 Hz until Ca2+ transient amplitude 
and sarcomere shortening reached steady-state. Again, following the last pulse, cells were 
perfused for 30 s with a 0Na+/0Ca2+ solution including 1 mmol/L of the RyR2 inhibitor 
tetracaine. As a consequence, SR Ca2+ leak into the cytoplasm was prevented. SR Ca2+ leak 
was estimated as the difference between the Fura-2 ratio recorded at the end of the 
0Na+/0Ca2+ Ringer’s perfusion with and without tetracaine. At the end of this protocol, 
tetracaine was washed out for at least 60 seconds and 10 mmol/L caffeine was applied to 
evaluate the total SR Ca2+ content. 
Ca2+ transient amplitude was measured by dividing the twitch amplitude (difference between 
the end-diastolic and the peak systolic ratios) by the end-diastolic ratio, thus corresponding 
to the percentage of variation in the Fura-2 ratio. Similarly, sarcomere shortening was 
assessed by its percentage of variation, which is obtained by dividing the twitch amplitude 
(difference between the end-diastolic and the peak systolic sarcomere length) by the end-
diastolic sarcomere length. Relaxation was assessed by measuring the time-to-50% 
relaxation from the time to peak shortening, and the Ca2+ transient decay was evaluated by 
measuring the time-to-50% decay of the Fura-2 ratio from the time to peak ratio. SR Ca2+ 
leak was measured by subtracting the ratio of fluorescence recorded in steady-state in 
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0Na+/0Ca2+ Ringer’s with tetracaine from the ratio recorded in steady-state in 0Na+/0Ca2+ 
Ringer’s without tetracaine. SR Ca2+ load was estimated by dividing the amplitude of the 
caffeine-induced twitch (difference between the peak ratio obtained with caffeine and the 
diastolic ratio measured before tetracaine treatment) by the diastolic ratio. Fractional release 
was calculated by dividing the Ca2+ transient amplitude by the caffeine-induced twitch 
amplitude, thus corresponds to the fraction of Ca2+ released from the SR during a twitch. All 
parameters were calculated offline using IonWizard 6 (IonOptix).  
 
Ca2+ spark analysis 
Mice were sacrificed under isoflurane anesthesia (5% v/v) by cervical dislocation. 100 I.U. 
heparin was administered by intraperitoneal injection prior to isolation, to ensure sufficient 
perfusion of myocardium. Explanted hearts were retrogradely perfused on a Langendorff 
system, first with a Ca2+ free solution containing (in mmol/L) NaCl 113, KCl 4.7, KH2PO4 0.6, 
Na2HPO4x2H2O 0.6, MgSO4x7H2O 1.2, NaHCO3 12, KHCO3 10, HEPES 10, taurine 30, BDM 
10, glucose 5.5, phenol-red 0.032 (37°C, pH 7.4), followed by the addition of 7.5 mg/ml 
liberase 1 (Roche diagnostics) and trypsin 0.6% (Life Technologies) as well as 0.125 mmol/L 
CaCl2. Upon becoming flaccid, ventricular and atrial myocardium were separated. Ventricular 
myocardium was cut into small pieces and dispersed in solution. Ca2+ concentration was 
increased in steps every 7 min until desired concentration was reached. Cells were plated on 
laminin-coated recording chambers and left to settle for 20 min. 
Isolated mouse ventricular cardiac myocytes were incubated for 15 min at room temperature 
with a Fluo-3 AM loading buffer (10 μmol/L, Molecular Probes). Experimental solution 
contained (in mmol/L): KCl 4, NaCl 140, MgCl2 1, HEPES 5, glucose 10, CaCl2 2 (pH 7.4, 
NaOH, room temperature) plus isoproterenol (ISO) 100 nmol/L for the ISO experiments. 
Myocytes were superfused with experimental solution for 5-10 min before experiments 
commenced and during experiments to remove excess indicator and to allow time for 
complete deesterification of Fluo-3 AM. Ca2+ spark measurements were carried out on a 
laser scanning confocal microscope (LSM 5 Pascal, Zeiss) with a 40x oil-immersion 
objective. Fluo-3 was excited by an argon ion laser (488 nm). Emitted fluorescence was 
collected through a 505 nm long-pass emission filter. Fluorescence images were recorded in 
the line-scan mode (width of scan line: 38.4 μm, 512 pixels per line, pixel time: 0.64 μs, 
number of unidirectional line scans: 10,000, measurement period: 7.68 s). Confocal line 
scans were performed at rest after a brief period of field stimulation to load the SR (10 
pulses, 1 Hz, 20 V). Ca2+ sparks were analyzed in SparkMaster for ImageJ. Mean spark 
frequency (CaSpF) was normalized to cell width and scan rate (100 μm-1*s-1).  
 
Immunoblot analysis 
Protein samples were prepared from pulverized ventricular myocardium and lyzed in buffer 
containing  30 mmol/L Tris/HCl (pH 8.8), 5 mmol/L EDTA, 30 mmol/L NaF, 3% SDS, and 
10% glycerol. Samples were separated in denaturizing acrylamide gels and subsequently 
transferred onto nitrocellulose or PVDF membranes. After blocking the membranes with 
Roti®-block (Carl Roth) for 1 h, the incubation with anti-PDE2 (1:1,000, FabGennix), anti-
calsequestrin (1:1,000, ThermoScientific), and anti-α-tubulin (1:2,000, Sigma-Aldrich) was 
carried out over night at 4°C. After incubation with appropriate secondary antibodies for 1 h, 
proteins were visualized by enhanced chemoluminescence and quantified with Quantity One 
software (Biorad). 
 
Measurement of infarct size  
Hearts were fixed in 4% (m/V) paraformaldehyde and embedded in paraffin. Hearts were 
sliced transversely (2 µm). Sections of the midpapillary region were stained with Sirius Red 
as described previously11, 12. For the determination of the infarct size, the epicardial and 
endocardial infarct length and circumference was measured. Infarct size was calculated as 
follows: [(epicardial infarct length/ epicardial circumference) + (endocardial infarct 
length/endocardial circumference)/2] * 100 13. 
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Online Figures 
 
Online Figure I. ISO infusion induces left ventricular hypertrophy. Relative left 
ventricular weight (LVW) determined by echocardiography to body weight (BW) ratio in mice 
subjected to chronic ISO infusions (30 mg/kg/d for 7d) or NaCl (0.9%) as control; n=7-9. 
Statistical significance was determined by Student’s t-test. *p<0.05 vs. NaCl. 
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Online Figure II. Effect of PDE2-specific inhibitor BAY 60-7550 on hemodynamic 
parameters in beagle dogs. Effect of PDE2 inhibition in dogs exposed to the indicated 
doses of BAY 60-7550 (i.d.). Animals were anaesthetized, equipped with catheters 
(abdominal aorta, left ventricle and ascending aorta) and monitored by echocardiography 
over a period of 240 min post application. (A) Maximal increase in heart rate (HR) given as % 
over respective basal HR. (B) Table with assessed hemodynamic parameters at the time 
point of maximal increase in heart rate (HR): systolic and diastolic blood pressure (BPs, 
BPd), left ventricular pressure (LVP), cardiac output (CO), stroke volume (SV). Average of 
n=3 for each group. Statistical significance was determined by one-way ANOVA. *p<0.05 for 
linear trend. 
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Online Figure III. Characterization of the lower expressing transgenic mouse line TG-
4808. Echocardiographic determination of fractional area shortening (FAS, A), cardiac output 
(CO, B), and heart rate (HR, C) in anaesthetized 2 month old mice. Animals were treated 
with 10 mg/kg dobutamine (DOBU, i.p.) 2 min prior to measurements when indicated. (D) 
Left ventricular weight (LVW) calculated from the echocardiographic data and normalized to 
tibia length; n=12-14 for each group. (E, F) Lysates prepared from ventricular myocardium 
were analyzed by immunoblot with the indicated specific antibodies. PDE2 expression was 
normalized to tubulin and given relative to WT. (E) Immunoblots and (F) quantification; n=2 
for each group Statistical significance was determined by one-way ANOVA followed by 
Newman-Keuls multiple comparison Test (A, C) and by Student’s t-test (B, D). #p<0.05 vs. 
respective basal. 
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Online Figure IV. Characterization of the high expresser transgenic mouse line TG-
4811. Echocardiographic determination of fractional area shortening (FAS, A), cardiac output 
(CO, B), and heart rate (HR, C) in anaesthetized 2 month old mice. Animals were additionally 
treated with 10 mg/kg dobutamine (DOBU, i.p.) 2 min prior to measurements when indicated. 
(D) Left ventricular weight (LVW) calculated from the echocardiographic data and normalized 
to body weight (BW); n=6-8 for each group. (E, F) Lysates prepared from ventricular 
myocardium were analyzed by immunoblot with the indicated specific antibodies. PDE2 
expression was normalized to tubulin and given relative to WT. (E) Immunoblots and (F) 
quantification; n=2 for each group. Statistical significance was determined by one-way 
ANOVA followed by Newman-Keuls multiple comparison test (A, C) and by Student’s t-test 
(B, D). *p<0.05 vs. WT, #p<0.05 vs. respective basal. 
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Online Figure V. Metoprolol reduced heart rate to a similar extent in WT and PDE2-TG, 
while basal hypercontractility of PDE2-TG was independent of β-AR activity. 
Echocardiographic determination of heart rate (HR, A) and fractional area shortening (FAS, 
C) in anaesthetized mice in the presence of increasing metoprolol doses (1, 3, 10, 30, 100 
mg/kg, i.p.). (B, D) Normalization of A and C to compare potency.  
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Online Figure VI. ECG-Telemetry: Activity pattern and Poincaré plots of RR intervals 
documented over a period of 24 h. Application of HCN-Blocker Ivabradine (IVA). 
Animals (n=4 per genotype) were monitored by ECG-telemetry for a period of 72 h to 
calculate average changes in activity of a 24 h cycle. Activity was tracked as an avarage of 1 
min intervals. (A) Average circadian changes in activity. (B) Average activity during day and 
night periods. Statistical significance was determined by one-way ANOVA followed by 
Newman-Keuls multiple comparison test. #p<0.05 vs. respective basal. (C, D) Representative 
Poincaré plot of a WT an TG animal regarding the distribution of daily RR intervals. Sinus 
arrest and AV block were excluded. (E) Average traces of IVA-application 45 min prior and 2 
h after ivabradine (IVA) injection (5 mg/kg, i.p.). Frequencies were tracked as average of 5 s 
intervals; n=5. 
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Online Figure VII. PDE2 overexpression attenuates β-AR stimulation of Ca2+ transients 
and sarcomere shortening in cardiomyocytes. Adult ventricular myocytes isolated from 
WT or PDE2-TG mice were loaded with Fura-2 and stimulated at a frequency of 0.5 Hz in the 
absence or presence of increasing concentrations of ISO. Sarcomere length and Fura-2 ratio 
were recorded using an IonOptix System. Concentration-response relationship was 
extrapolated for WT cardiomyocytes under the assumption that 100 nmol/L ISO is sufficient 
for maximal responsivness. (A) Average amplitudes of sarcomere shortening. (B) 
Normalization of (A) to compare logEC50 values with lowest values set to 0% and highest 
values set to 100%. (C) Average amplitudes of Ca2+ transients. (D) Normalization of (C) to 
compare logEC50 values with lowest values equal 0% and highest values equal 100%. (E). 
Average amplitudes of half-time relaxation of sarcomere shortening (t1/2 off). (F) Average 
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amplitudes of half-time relaxation of Ca2+ transients (t1/2 off). n=3-6 animals/genotype with 6-
20 cells in each group. Data sets were subjected to comparison of fit (extra sum-of-squares F 
test) regarding top values (efficacy) or logEC50 (potency). *p<0.05 vs. WT. 
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Online Figure VIII. Arrhythmia study in healthy mice. Heart rate was monitored after 
double ISO injection (2 mg/kg, i.p.; time intervall between injections 30 min) and analyzed for 
arrhythmic events such as ventricular extra systoles, bigeminy, salvos and VTs over a period 
of 90 min; n=7. (A) Average ISO-induced ventricular extra systoles (VES including salvos 
and ventricular tachycardia) per minute. Regular occurence of VES 15 min after the second 
injection of ISO in all animals. (B) Occurrence of bigemeny (BG) and (C) salvos in addition to 
main Fig. 4. Statistical significance was determined by Fisher’s exact test to compare 
occurrence of events. 
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Online Figure IX. SR Ca2+ leak (A) Representative traces of Ca2+ transients, sarcoplasmic 
reticulum (SR) Ca2+ leak and load measured in Fura-2 loaded adult mouse ventricular 
myocytes from WT (left) or PDE2-TG mouse (right) paced at 1 Hz, upon ISO (100 nmol/L) 
application. Tetracaine (1 mmol/L) was used to estimate SR Ca2+ leak, caffeine (10 mmol/L) 
to measure SR Ca2+ load. (B) Mean amplitude of the SR Ca2+ leak recorded in control or 
ISO. n=3 animals/genotype with 7-10 cells in each group. Statistical significance was 
determined by one-way ANOVA followed by Newman-Keuls multiple comparison test. 
*p<0.05 vs. WT, #p<0.05 vs. respective basal. 
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Online Figure X. Echocardiographic parameters and heat weights after MI. 
Echocardiographic analysis 14 d post MI of (A) heart rate, (B) stroke volume, (C) left 
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ventricular inner end-diastolic diameter and (D) left ventricular posterior wall end-diastolic 
diameter. Biometric data included determination of (E) heart weight (HW) to tibia length 
ratios, (F) lung weight (LW) to tibia length ratios, (G) body weight (BW) and (H) tibia length. 
Statistical significance was determined by Student’s t-test. *p<0.05 vs. WT. 
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